Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17379063rdf:typepubmed:Citationlld:pubmed
pubmed-article:17379063lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C1332225lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C1134535lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C2347880lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C1831743lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C0338248lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:17379063lifeskim:mentionsumls-concept:C0919274lld:lifeskim
pubmed-article:17379063pubmed:issue4lld:pubmed
pubmed-article:17379063pubmed:dateCreated2007-3-23lld:pubmed
pubmed-article:17379063pubmed:abstractTextTo determine the safety and outcome following standard-dose ibritumomab tiuxetan followed by BEAM high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.lld:pubmed
pubmed-article:17379063pubmed:languageenglld:pubmed
pubmed-article:17379063pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:citationSubsetIMlld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17379063pubmed:statusMEDLINElld:pubmed
pubmed-article:17379063pubmed:monthAprlld:pubmed
pubmed-article:17379063pubmed:issn0301-472Xlld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:Ben-BassatIsa...lld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:NaglerArnonAlld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:ShimoniAvicha...lld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:AvigdorAbraha...lld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:HardanIzharIlld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:YerushalmiRon...lld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:OksmanYakovYlld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:ZwasS TzilaSTlld:pubmed
pubmed-article:17379063pubmed:authorpubmed-author:Shem-TovNogaNlld:pubmed
pubmed-article:17379063pubmed:issnTypePrintlld:pubmed
pubmed-article:17379063pubmed:volume35lld:pubmed
pubmed-article:17379063pubmed:ownerNLMlld:pubmed
pubmed-article:17379063pubmed:authorsCompleteYlld:pubmed
pubmed-article:17379063pubmed:pagination534-40lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:meshHeadingpubmed-meshheading:17379063...lld:pubmed
pubmed-article:17379063pubmed:year2007lld:pubmed
pubmed-article:17379063pubmed:articleTitleYttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.lld:pubmed
pubmed-article:17379063pubmed:affiliationDivision of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.illld:pubmed
pubmed-article:17379063pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17379063pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17379063lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17379063lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17379063lld:pubmed